Department of Urology, Bordeaux University Hospital, Bordeaux, France.
SOPHiA GENETICS, Radiomics R&D Department, Pessac, France.
BJU Int. 2023 Aug;132(2):160-169. doi: 10.1111/bju.15959. Epub 2023 Feb 1.
To assess the impact of pathological upstaging from clinically localized to locally advanced pT3a on survival in patients with renal cell carcinoma (RCC), as well as the oncological safety of various surgical approaches in this setting, and to develop a machine-learning-based, contemporary, clinically relevant model for individual preoperative prediction of pT3a upstaging.
Clinical data from patients treated with either partial nephrectomy (PN) or radical nephrectomy (RN) for cT1/cT2a RCC from 2000 to 2019, included in the French multi-institutional kidney cancer database UroCCR, were retrospectively analysed. Seven machine-learning algorithms were applied to the cohort after a training/testing split to develop a predictive model for upstaging to pT3a. Survival curves for disease-free survival (DFS) and overall survival (OS) rates were compared between PN and RN after G-computation for pT3a tumours.
A total of 4395 patients were included, among whom 667 patients (15%, 337 PN and 330 RN) had a pT3a-upstaged RCC. The UroCCR-15 predictive model presented an area under the receiver-operating characteristic curve of 0.77. Survival analysis after adjustment for confounders showed no difference in DFS or OS for PN vs RN in pT3a tumours (DFS: hazard ratio [HR] 1.08, P = 0.7; OS: HR 1.03, P > 0.9).
Our study shows that machine-learning technology can play a useful role in the evaluation and prognosis of upstaged RCC. In the context of incidental upstaging, PN does not compromise oncological outcomes, even for large tumour sizes.
评估从临床局限性 pT3a 到局部进展期 pT3a 的病理升级对肾细胞癌 (RCC) 患者生存的影响,以及在这种情况下各种手术方法的肿瘤安全性,并开发一种基于机器学习的、现代的、与临床相关的模型,用于个体术前预测 pT3a 升级。
回顾性分析了纳入法国多机构肾癌数据库 UroCCR 的 2000 年至 2019 年接受部分肾切除术 (PN) 或根治性肾切除术 (RN) 治疗 cT1/cT2a RCC 的患者的临床数据。在训练/测试分割后,该队列应用了七种机器学习算法来开发 pT3a 升级的预测模型。对 pT3a 肿瘤进行 G 计算后,比较了 PN 和 RN 后无复发生存 (DFS) 和总生存 (OS) 率的生存曲线。
共纳入 4395 例患者,其中 667 例 (15%,337 例 PN 和 330 例 RN) 为 pT3a 升级 RCC。UroCCR-15 预测模型的受试者工作特征曲线下面积为 0.77。调整混杂因素后的生存分析显示,pT3a 肿瘤中 PN 与 RN 在 DFS 或 OS 方面无差异 (DFS:风险比 [HR] 1.08,P = 0.7;OS:HR 1.03,P > 0.9)。
我们的研究表明,机器学习技术在评估和预测升级 RCC 方面可以发挥有用的作用。在偶然升级的情况下,PN 不会影响肿瘤学结果,即使对于较大的肿瘤大小也是如此。